Hutchmed China Limited (HCM) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
Hutchmed China Limited's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Hutchmed China Limited's ROI in the fourth quarter of 2025? Hutchmed china Limited achieved a return on average invested assets (ROI) of 31.67 % in its fourth quarter of 2025 a new company high.
ROI has improved compared to 2.89% in the third quarter of 2025, due to net income growth.
Within the Healthcare sector 48 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Dec 31 2025 quarter, so far to 190, from total ROI ranking in the third quarter of 2025 at 1431.
HUTCHMED (China) Limited, a prominent biopharmaceutical company dedicated to advancing innovative oncology and hematology treatments, has announced the appointment of Dr. Chaohong Hu (Dr. Mary Hu) as an Independent Non-executive Director and member of the Board s Technical Committee, effective November 21, 2024. This strategic appointment reflects HUTCHMED’s commitment to enhancing its governance and technical expertise amid its ongoing growth trajectory in the competitive pharmaceutical landscape.Dr. Hu s extensive background in clinical research, coupled with her proven leadership experience, positions her as a valuable asset to HUTCHMED’s board. Her addition is anticipated to bolster the company s strategic decision-making processes, particularly as it aims to expand its portfolio of cutting-edge therapeutic solutions.
HUTCHMED s TAGRISSO and ORPATHYS Combination Shows Promising Efficacy in MET-Driven Lung Cancer: A New Benchmark in ROI Achieved New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer Hutchmed China Limited has announced impressive results from its SAVANNAH Phase II trial, which evaluated the efficacy of TAGRISSO (osimertinib) in combination with ORPATHYS (savolitinib) for patients with lung cancer characterised by high levels of MET overexpression and/or amplification. The trial revealed a high and clinically meaningful response rate, showcasing the promising potential of this oral treatment combination to effectively combat MET-driven resistance in patients with EGFR-mutated lung cancer.The SAVANNAH Phase II trial s findings highlight the significant benefits that the TAGRISSO-ORPATHYS combination may offer to lung cancer patients, particularly those who exhibit resistance due to MET overexpression and amplification. This is an important development in the realm of precision medicine, providing a targeted approach to tackling one of the most challenging mutations in lung cancer.
Voluntary Withdrawal of Supplemental NDA for FruquintinibHONG KONG, SHANGHAI, and FLORHAM PARK, N.J. Aug. 30, 2024 - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) has announced the voluntary withdrawal of its supplemental New Drug Application (NDA) in China for the combination of fruquintinib and paclitaxel. This application was aimed at treating second-line advanced gastric or gastroesophageal junction adenocarcinoma. Following a meticulous internal review and recent discussions with the National Medical Products Administration of China (NMPA), HUTCHMED concluded that the current data package would unlikely support an approval at this time. The decision underscores HUTCHMED’s commitment to high standards of clinical efficacy and regulatory compliance. The company has expressed its intent to evaluate alternative pathways forward, signaling the firm’s dedication to finding effective treatments for this patient population. of Menin Inhibitor HMPL-506: A New Hope for Hematological MalignanciesIn a related move intended to expand its innovation in the oncology space, HUTCHMED previously announced on June 6, 2024, the initiation of a Phase I clinical trial for its menin inhibitor, HMPL-506, in patients with hematological malignancies. The first patient received their dose on May 31, 2024. This trial marks a significant step forward in assessing the safety and tolerability of HMPL-506, showcasing HUTCHMED’s strategic pivot towards addressing unmet needs in hematology.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
